Otros idiomas Anebulo Pharmaceuticals, Inc.

Acciones

ANEB

US0345691036

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,96 ^USD	+2,07 %		+6,09 %	+22,31 %

13/02	Anebulo Pharmaceuticals, Inc. informa de los resultados del segundo trimestre y de los seis meses que finalizaron el 31 de diciembre de 2023	CI
2023	Anebulo Pharmaceuticals, Inc. informa de los resultados del primer trimestre finalizado el 30 de septiembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates	13/02
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates	14/11
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors	09/10/23
Anebulo Pharmaceuticals Announces New CEO	09/10/23
Anebulo Pharmaceuticals Appoints New CEO	06/10/23
Anebulo Pharmaceuticals Announces New CEO	06/10/23
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors	06/10/23
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO	06/10/23
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors	06/10/23
Anebulo Pharmaceuticals Appoints Daniel George as Part-Time Finance Chief	29/09/23
Anebulo Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	29/09/23
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer	29/09/23
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates	20/09/23
Anebulo Pharmaceuticals : Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates - Form 8-K	20/09/23
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	20/09/23
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer	18/09/23
Anebulo Pharmaceuticals, Inc. Announces Resignation of Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer	05/09/23
Anebulo Pharmaceuticals, Inc. Announces Sandra A. Gardiner Resigns as Acting Chief Financial Officer	05/09/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Anebulo Pharmaceuticals, Inc.

Acciones

ANEB

US0345691036

Otros idiomas

Filtros